Get started
2cureX AB2cureX AB2cureX AB

2cureX AB

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsSeasonals

Documents


Explore the latest documents from the company, including regulatory filings and corporate disclosures that offer insight into company performance and strategy. Use these resources to support informed investment decisions.
2026
Investor update
May 20, 2026
Expanding into functional precision medicine with U.S. partnerships and a data-driven platform.
2025
Earnings, H2 FY2025
Annual
Feb 26, 2026
No revenue in 2025, but strategic collaborations and strong investor backing drive future focus.
Earnings, H1 FY2025
Aug 21, 2025
Direct-to-patient model validated, financials improved, and expansion accelerates in H1 2025.
2024
Earnings, H2 FY2024
Annual
Feb 27, 2025
Transformation year with new strategy, improved cash flow, and leadership renewal.
Investor Update
Sep 24, 2024
Leadership changes and a new direct-to-patient strategy follow the sale of key assets.
Earnings, H1 FY2024
Aug 22, 2024
Restructuring and new financing position 2cureX for a direct-to-patient oncology strategy.
2023
Earnings, Q4 FY2023
Annual
Feb 22, 2024
Earnings, Q3 FY2023
Nov 23, 2023
Investor Update
Oct 26, 2023
Earnings, Q2 FY2023
Aug 24, 2023
Investor Update
Jul 12, 2023
Earnings, Q1 FY2023
May 25, 2023
Investor Update
Apr 12, 2023
2022
Earnings, Q4 FY2022
Annual
Feb 24, 2023
Earnings, Q3 FY2022
Nov 24, 2022
Earnings, Q2 FY2022
Aug 25, 2022
Earnings, Q1 FY2022
May 24, 2022